Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

Homepage

Finance

Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

Related

Natera director Marcus Gail Boxer sells $590,773 in stock

Natera executive chairman sells $7.39 million in stock

ACM Research CFO Mark McKechnie sells $411,300 in stock

Trending

Popular

College football by the odds: Vegas picks and preview of Ohi...

TOUS les JOURS Opens in Henderson!

Sole mates: Find the perfect shoes for your fitness journey

Australian whose blood saved 2.4 million babies dies

Electric Air Taxis may be Coming to Las Vegas